

# HSIE Results Daily

## Contents

### Results Reviews

- Relaxo Footwears:** Top-line declined 2.3% YoY to INR7.47bn in Q4 (HSIE: INR8.03bn) as BIS implementation in Q4 impacted January volumes (volume/net realisation grew -3.8%/1.6% YoY for Q4). Impact was largely in closed footwear, while open footwear continued to clock healthy volume growth. The revenue mix stood at 38/25/37% for Relaxo+Bahamas/Flite/Sparx. GM/EBITDAM expanded 840/68bps YoY to 51.1/16.1%. Management continues to guide for – double-digit volume growth and EBITDAM of 15-16% in FY25. We've accordingly toned down our FY25/26 EPS estimates by 7/5% respectively to account for higher A&P/channel incentives and maintain SELL on the stock with a DCF-based TP of INR750/sh, implying 46x FY26E P/E.
- Alkyl Amines:** We maintain SELL on Alkyl Amines (AAKL) with a price target of INR 1,763 (WACC 12%, terminal growth 5%). The stock is currently trading at ~46/37x FY25/26E EPS. We remain cautious given the weakness in the underlying demand and competition from Chinese and domestic players. EBITDA/APAT were 5/14% above our expectations, owing to lower-than-expected raw material costs.
- HG Infra:** HG Infra (HG) reported its quarterly revenue/EBITDA/APAT of INR 16.3/2.6/1.6bn, a miss by 5/2/0.1%. The OB as of Mar'24 stood at INR 124.3bn (~2.4x FY24 revenue). The company has provided its FY25 revenue guidance at ~INR 60bn (~15-20% YoY) with an EBITDA margin of ~16%. On the order inflow front, the company expects INR 110-120bn, with INR 80/10/20bn from highways/solar and water/ railways. In FY24, HG made a pivotal shift in its OB inflows from road to railways/solar, indicating its robust expansion strategy. Equity infusion guidance for FY25/26/27 stands at INR 5.1/1.3/1.3bn for roads and INR 2.7/2.7/0bn for solar. The standalone gross/net debt, as of Mar'23 stood at INR 4.5/2.6bn vs. INR 4.7/3.3bn, as of Dec'23. We have increased our EPS estimates to reflect better revenue growth and EBITDA margins. Given robust OB, likely pick-up in project execution and a healthy balance sheet, we maintain BUY on HG, with an increased TP of INR 1,521 (14x Mar-26E EPS, HAM assets at INR 149/sh).
- Dilip Buildcon:** Dilip Buildcon (DBL) reported a revenue/EBITDA/APAT miss of 2.3/6.2/11.3%. In Q4FY24, DBL won two projects worth INR 10bn, taking FY24 order wins to INR 36bn. With this, the Mar'24 OB stood at INR 174.3bn (~1.7x FY24 revenue). Moreover, a major fall in order inflows has been on the back of elections, but DBL expects strong order flows in H2FY25 from all sectors. The standalone net debt as of Mar'24 stood at INR 15.1bn vs. INR 18.2bn as of Dec'23, with net D/E at 0.29x. It reiterated its guidance for reducing the debt by INR 5bn by FY25 and becoming net cash by FY26. Furthermore, it is planning to float its own InvIT with Alpha Alternatives (AA) as a strategic partner and expects INR 20/40bn in cash/InvIT units by FY25-end. Given weak inflow, we cut revenue and margins estimates, which is partly offset by lower interest costs on reducing debt; we recalibrate our FY24/25/26 EPS lower. We increase our P/E multiple from 10x to 12x, given robust deleveraging and asset monetisation. We maintain ADD with an increased SOTP-based TP of INR 529/sh (12x Mar-26E EPS, 1.2x P/BV HAM equity investment).

HSIE Research Team

hdfcsec-research@hdfcsec.com

# Relaxo Footwears

## BIS implementation impacts volumes

Top-line declined 2.3% YoY to INR7.47bn in Q4 (HSIE: INR8.03bn) as BIS implementation in Q4 impacted January volumes (volume/net realisation grew -3.8%/1.6% YoY for Q4). Impact was largely in closed footwear, while open footwear continued to clock healthy volume growth. The revenue mix stood at 38/25/37% for Relaxo+Bahamas/Flite/Sparx. GM/EBITDAM expanded 840/68bps YoY to 51.1/16.1%. Management continues to guide for – double-digit volume growth and EBITDAM of 15-16% in FY25. We've accordingly toned down our FY25/26 EPS estimates by 7/5% respectively to account for higher A&P/channel incentives and maintain SELL on the stock with a DCF-based TP of INR750/sh, implying 46x FY26E P/E.

- Q4FY24 highlights:** Revenue declined 2.3% YoY to INR7.47bn in Q4FY24 (HSIE: INR8.03bn). Volume/net realisation grew -3.8%/1.6% YoY. BIS implementation in Q4 impacted the volume sold for the month of Jan-24. The company clocked strong volume growth in open footwear in Q4. The revenue mix stood at 25/37/38% for Relaxo+Bahamas/Flite/Sparx. Management continues to guide for double-digit volume growth and EBITDAM of 15-16% in FY25. GM expanded 840bps YoY to 51.1% (HSIE: 47.6%), led by (1) softening of RM price and (2) a price hike due to BIS implementation. Current level of GM to persist (per management). GM gains didn't trickle down at the EBITDAM level (expanded 68bps YoY to 16.1%; HSIE: 15.8%) courtesy higher employee and technology expenses. EBITDA/APAT grew 2/-3% YoY to INR 1.2bn/614mn in Q4 (HSIE: 1.27bn/696mn). Subdued demand and slower payments have impacted receivables (inched up to 45 days vs 35 days in FY23). Capex in FY24 increased to INR 2.49bn (vs. INR 1.84bn in FY23) courtesy purchase of a land parcel in Rajasthan. Manufacturing plants are operating at 65% capacity utilization.
- Outlook:** Relaxo remains a strong category leader, well-poised to gain market share within an immature ecosystem. Margins seem to have bottomed out in FY24. Profitability comeback is already priced in. At 51x FY26 P/E, we suspect that further stock upside seems limited. We've cut our FY25/26 EPS estimates by 7/5% respectively to account for higher A&P/channel incentives and maintain our SELL rating on the name with a DCF-based TP of INR750/sh, implying 46x FY26E P/E.

### Quarterly financial summary

(INR mn)	4Q FY24	4Q FY23	YoY (%)	3Q FY24	QoQ (%)	FY22	FY23	FY24	FY25E	FY26E
Net Revenue	7,472	7,649	(2.3)	7,127	4.8	26,533	27,828	29,141	33,964	39,210
EBITDA	1,204	1,180	2.0	872	38.1	3,765	2,847	3,476	5,398	6,486
APAT	614	633	(3.0)	386	59.2	2,327	1,545	2,005	3,252	4,095
EPS (Rs)	2.5	2.6	(3.0)	1.6	59.2	9.3	6.2	8.1	13.1	16.4
P/E (x)						90.0	135.6	104.5	64.4	51.1
EV/EBITDA (x)						55.2	72.6	59.8	38.0	31.4
Core RoCE(%)						16.4	9.3	11.8	19.0	22.7

Source: Company, HSIE Research, Standalone Financials

### Change in estimates

(Rs mn)	FY24			FY25E			FY26E		
	New	Old	Change (%)	New	Old	Change (%)	New	Old	Change (%)
Revenue	29,141	29,696	(1.9)	33,964	34,601	(1.8)	39,210	39,574	(0.9)
EBITDA	3,476	4,177	(16.8)	5,398	5,490	(1.7)	6,486	6,655	(2.5)
EBITDA margin (%)	11.9	14.1	(214 bps)	15.9	15.9	3 bps	16.5	16.8	(27 bps)
APAT	2,005	2,532	(20.8)	3,252	3,492	(6.9)	4,095	4,327	(5.4)
APAT margin (%)	6.9	8.5	(165 bps)	9.6	10.1	(52 bps)	10.4	10.9	(49 bps)
EPS (Rs)	8.1	10.2	(20.8)	13.1	14.0	(6.9)	16.4	17.4	(5.4)

Source: Company, HSIE Research, Standalone Financials

## SELL

CMP (as on 10 May 2024) INR 851

Target Price INR 750

NIFTY 22,055

KEY CHANGES	OLD	NEW
Rating	SELL	SELL
Price Target	INR750	INR750
EPS %	FY25E	FY26E
	-6.9	-5.4

### KEY STOCK DATA

Bloomberg code	RLXF IN
No. of Shares (mn)	249
MCap (INR bn) / (\$ mn)	212/2,538
6m avg traded value (INR mn)	77
52 Week high / low	INR 974/762

### STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	(0.1)	(6.0)	(2.0)
Relative (%)	(1.6)	(17.9)	(19.3)

### SHAREHOLDING PATTERN (%)

	Dec-23	Mar-24
Promoters	71.27	71.27
FIs & Local MFs	8.81	9.33
FPIs	3.40	3.32
Public & Others	16.52	16.08
Pledged Shares	0	0

Source : BSE

Pledged shares as % of total shares

**Jay Gandhi**

jay.gandhi@hdfcsec.com  
+91-22-6171-7320

**Tanuj Pandia**

tanuj.pandia@hdfcsec.com  
+91-22-6171-7348

# Alkyl Amines

## Competitive pressure, Pharma to boost growth

We maintain SELL on Alkyl Amines (AACL) with a price target of INR 1,763 (WACC 12%, terminal growth 5%). The stock is currently trading at ~46/37x FY25/26E EPS. We remain cautious given the weakness in the underlying demand and competition from Chinese and domestic players. EBITDA/APAT were 5/14% above our expectations, owing to lower-than-expected raw material costs.

### Financial performance:

- Revenue came at -13/11% YoY/QoQ to INR 3.56 bn owing to pricing pressure from Chinese manufacturers. EBITDA margin improved to 19.3% (62/ 81bps YoY/QoQ) due to a decrease in raw material prices. Other operating expenses increased to 0.83 bn (-8.8/17.8% YoY/QoQ) due to provision for CSR expense, impairment of unused assets at Patalganga, increased power and fuel expenses. We expect to improve margins in the subsequent quarter with a) stabilization of raw material prices and b) ramp up of newly commissioned plant.

### Key takeaways:

- Company capitalized capex of INR 3.75 bn incurred for the ethylamine plant.
- During FY24, the company incurred capex of INR 1.2 billion, mainly for the maintenance capex and solar plant.
- Volume growth was ~10%, primarily impacted by acetonitrile and mono isopropyl. It was balanced out with downstream products of methylamine. In FY24, overall capacity utilization was ~55% to ~60% for the Acetonitrile plant owing to aggressive selling in the Indian market by Chinese manufacturers.
- New Ethylamine plant was running at ~60% of capacity in post commissioning in Oct-23. AACL has headroom available in this new plant. AACL expects volume growth of ~10-15% in FY25 on the back of growing demand from Pharma customers.
- AACL has taken initiatives like the installation of solar facilities and a steam-generated power plant which has helped save power and fuel costs. The company has commissioned 3.5 MW solar capacity. A total solar capacity of 8.5 MW is expected to save ~INR 80 million.

### Financial summary

INR mn	4Q FY24	3Q FY24	QoQ (%)	3Q FY23	YoY (%)	FY22	FY23	FY24P	FY25E	FY26E
Net Sales	3,566	3,220	10.8	4,117	(13.4)	15,420	16,823	14,406	18,034	22,637
EBITDA	689	596	15.6	769	(10.5)	3,252	3,431	2,507	3,556	4,307
APAT	385	334	15.2	486	(20.9)	2,249	2,287	1,489	2,218	2,726
AEPS (INR)	7.5	6.5	15.2	9.5	(20.9)	44.0	44.7	29.1	43.4	53.3
P/E (x)						44.9	44.2	67.9	45.6	37.1
EV/EBITDA(x)						31.0	29.6	40.2	28.3	23.1
RoE (%)						25.2	21.2	12.2	16.4	17.5

Source: Company, HSIE Research

### Change in estimates

Y/E Mar	FY25E Old	FY25E New	% Ch	FY26E Old	FY26E New	% Ch
EBITDA (INR mn)	3,250	3,556	9.4	4,172	4,307	3.2
Adj. EPS (INR/sh)	39.4	43.4	10.2	52.0	53.3	2.6

Source: Company, HSIE Research

## SELL

CMP (as on 10 May 2024)	INR 1,977
Target Price	INR 1,763
NIFTY	22,055

KEY CHANGES	OLD	NEW
Rating	SELL	SELL
Price Target	INR 1,759	INR 1,763
EPS %	FY25E	FY26E
	10.2%	2.6%

### KEY STOCK DATA

Bloomberg code	AACL IN
No. of Shares (mn)	51
MCap (INR bn) / (\$ mn)	101/1,210
6m avg traded value (INR mn)	227
52 Week high / low	INR 2,798/1,805

### STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	(10.9)	(7.1)	(22.6)
Relative (%)	(12.4)	(19.0)	(39.9)

### SHAREHOLDING PATTERN (%)

	Dec-23	Mar-24
Promoters	71.96	71.96
FIs & Local MFs	1.07	1.10
FPIs	2.94	3.04
Public & Others	24.04	23.90
Pledged Shares	0.00	0.00

Source : BSE

### Nilesh Ghuge

nilesh.ghuge@hdfcsec.com  
+91-22-6171-7342

### Harshad Katkar

harshad.katkar@hdfcsec.com  
+91-22-6171-7319

### Prasad Vadnere

prasad.vadnere@hdfcsec.com  
+91-22-6171-7356

### Akshay Mane

akshay.mane@hdfcsec.com  
+91-22-6171-7330

# HG Infra

## Business expansion on track with a pivotal shift

HG Infra (HG) reported its quarterly revenue/EBITDA/APAT of INR 16.3/2.6/1.6bn, a miss by 5/2/0.1%. The OB as of Mar'24 stood at INR 124.3bn (~2.4x FY24 revenue). The company has provided its FY25 revenue guidance at ~INR 60bn (~15-20% YoY) with an EBITDA margin of ~16%. On the order inflow front, the company expects INR 110-120bn, with INR 80/10/20bn from highways/solar and water/ railways. In FY24, HG made a pivotal shift in its OB inflows from road to railways/solar, indicating its robust expansion strategy. Equity infusion guidance for FY25/26/27 stands at INR 5.1/1.3/1.3bn for roads and INR 2.7/2.7/0bn for solar. The standalone gross/net debt, as of Mar'23 stood at INR 4.5/2.6bn vs. INR 4.7/3.3bn, as of Dec'23. We have increased our EPS estimates to reflect better revenue growth and EBITDA margins. Given robust OB, likely pick-up in project execution and a healthy balance sheet, we maintain BUY on HG, with an increased TP of INR 1,521 (14x Mar-26E EPS, HAM assets at INR 149/sh).

- **Q4FY24 financial highlights:** Revenue of INR 16.3bn (+11/+21% YoY/QoQ, a miss by 5%). EBITDA: INR 2.6bn (+11.2/+23.5% YoY/QoQ, a miss by 2%). EBITDA margin came in at 16.2% (1.1/27.2bps YoY/QoQ, vs. our estimate of 15.8%). RPAT/APAT: INR 1.6/1.6bn (+8/+35% YoY/QoQ, in line). Its FY25 revenue growth guidance stands at ~15-20% with an EBITDA margin of ~16%.
- **Robust and well-diversified OB:** The OB as of Mar'24 stood at INR 124.3bn (~2.4x FY24 revenue). It is well-diversified at the client level, with government/private orders contributing toward 83/17%. 68% of the OB consisted of road orders, 21% belonged to railways and 11% from solar project orders. Geography-wise, 21% of orders were from Uttar Pradesh, followed by Jharkhand, Rajasthan, Maharashtra, Andhra Pradesh, Haryana, Karnataka and Telangana at 21/20/8/8/6/5/5%. Regarding the FY25 order inflow, the company expects to win orders worth INR 110bn.
- **Reduction in standalone debt levels:** The standalone gross/net debt, as of Mar'24 stood at INR 4.5/2.6bn vs. INR 4.7/3.3bn, as of Dec'23. The total equity requirement for 10 HAM projects stands at INR 14.6bn. Out of this, INR 6.9 bn has already been invested until Mar'24 and INR 5.1/ 1.3/1.3bn is to be invested in FY25/ FY26/ FY27. In addition, INR 5.4bn needs to be invested in its Solar business, of which INR 2.7/ INR2.7bn is expected to be infused in FY25/ FY26.

### Standalone financial summary – INR mn

YE Mar – INR mn	4QFY24	4QFY23	YoY (%)	3QFY24	QoQ (%)	FY23	FY24	FY25E	FY26E
Net Sales	16,345	14,696	11.2	13,464	21.4	44,185	51,217	59,634	70,368
EBITDA	2,646	2,377	11.3	2,142	23.5	7,103	8,220	9,275	10,935
APAT	1,588	1,477	7.5	1,181	34.5	4,214	4,654	5,294	6,385
EPS (INR)	24.4	22.7	7.5	18.1	34.5	64.7	71.4	81.2	98.0
P/E (x)						18.2	16.5	14.5	12.0
EV/EBITDA (x)						11.3	9.7	8.5	7.1
RoE (%)						26.8	22.7	20.9	20.9

Source: Company, HSIE Research

### Changes in Estimates

INR mn	FY25E			FY26E		
	New	Old	% Change	New	Old	% Change
Revenues	59,634	59,113	0.9	70,368	67,980	3.5
EBIDTA	9,275	9,159	1.3	10,935	10,419	4.9
EBIDTA Margins (%)	15.6	15.5	0.4	15.5	15.3	1.4
APAT	5,294	5,207	1.7	6,385	5,999	6.4

Source: Company, HSIE Research

## BUY

CMP (as on 10 May 2024) INR 1,181

Target Price INR 1,521

NIFTY 22,055

KEY CHANGES	OLD	NEW
Rating	BUY	BUY
Price Target	INR 1,381	INR 1,521
EPS Change %	FY25E 1.7	FY26E 6.4

### KEY STOCK DATA

Bloomberg code	HGINFRA
No. of Shares (mn)	65
MCap (INR bn) / (\$ mn)	77/922
6m avg traded value (INR mn)	204
52 Week high / low	INR 1,229/805

### STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	27.6	36.5	29.4
Relative (%)	26.1	24.6	12.1

### SHAREHOLDING PATTERN (%)

	Dec-23	Mar-24
Promoters	74.53	74.53
FIs & Local MFs	12.45	12.49
FPIs	1.56	1.68
Public & Others	11.47	11.3
Pledged Shares	-	-

Source: BSE

Parikshit D Kandpal, CFA

parikshitd.kandpal@hdfcsec.com  
+91-22-6171-7317

Jay Shah

jay.Shah1@hdfcsec.com  
+91-22-6171-7353

# Dilip Buildcon

## Resilient balance sheet amid muted order inflows

Dilip Buildcon (DBL) reported a revenue/EBITDA/APAT miss of 2.3/6.2/11.3%. In Q4FY24, DBL won two projects worth INR 10bn, taking FY24 order wins to INR 36bn. With this, the Mar'24 OB stood at INR 174.3bn (~1.7x FY24 revenue). Moreover, a major fall in order inflows has been on the back of elections, but DBL expects strong order flows in H2FY25 from all sectors. The standalone net debt as of Mar'24 stood at INR 15.1bn vs. INR 18.2bn as of Dec'23, with net D/E at 0.29x. It reiterated its guidance for reducing the debt by INR 5bn by FY25 and becoming net cash by FY26. Furthermore, it is planning to float its own InvIT with Alpha Alternatives (AA) as a strategic partner and expects INR 20/40bn in cash/InvIT units by FY25-end. Given weak inflow, we cut revenue and margins estimates, which is partly offset by lower interest costs on reducing debt; we recalibrate our FY24/25/26 EPS lower. We increase our P/E multiple from 10x to 12x, given robust deleveraging and asset monetisation. We maintain ADD with an increased SOTP-based TP of INR 529/sh (12x Mar-26E EPS, 1.2x P/BV HAM equity investment).

- Q4FY24 financial highlights:** Revenue: INR 29.3bn (+2.6/+14% YoY/QoQ, a 2.3% miss); EBITDA: INR 3.5bn (+29/+10%, YoY/QoQ, a 6.2% miss); EBITDA margin: 12% (+250/-36.4bps YoY/QoQ), vs. our estimate of 12.5%. RPAT: INR 1,237mn (+112/29.8% YoY/QoQ). Exceptional item: INR 163mn net gain arising on GST change in law and transfer of 51% stake in Bengaluru Nidagatta Chandikhole Highways Pvt Ltd to Shrem InvIT. APAT: INR 1,115mn (+168/39% YoY/QoQ, 11% miss). FY25 flat revenue growth guidance, with an EBITDA margin of 12-14%.
- Muted order inflows on the back of elections:** In Q4FY24, DBL won two projects worth INR 10bn, taking FY24 order wins to INR 36bn. With this, the Mar'24 OB stood at INR 174.3bn (~1.7x FY24 revenue). Roads /irrigation/water supply/ tunnel/metro/mining/other segments comprised 37/24/17/7/6/4% of the OB. At the contract level, EPC/HAM comprised 63/37% of the OB.
- Aiming for net cash status by FY26, strengthening balance sheet:** The standalone net debt as of Mar'24 stood at INR 15.1bn vs. INR 18.2bn as of Dec'23, with net D/E at 0.29x. The total equity requirement for 16 HAM projects and the Siarmal Coal Project stands at INR 27.6bn (21.8bn /5.8bn resp). DBL has invested equity of INR 14.2bn till Mar'24 and the company expects further equity investment of INR 5.9bn/ 4.2bn/ 2.3bn in FY25/ FY26/ FY27.

### Standalone Financial Summary (INR mn)

Particulars	4QFY24	4QFY23	YoY (%)	3QFY24	QoQ (%)	FY23	FY24	FY25E	FY26E
Net Sales	29,308	28,573	2.6	25,711	14.0	1,01,195	1,05,373	1,05,550	1,15,577
EBITDA	3,524	2,720	29.6	3,185	10.6	9,884	12,992	13,124	14,617
APAT	1,115	416	168.3	800	39.3	1,267	4,038	4,279	5,222
EPS (INR)	7.6	2.8	168.3	5.5	39.3	8.7	27.6	29.3	35.7
P/E (x)						54.4	17.1	16.1	13.2
EV/EBITDA (x)						9.4	6.5	6.6	6.0
RoE (%)						2.8	8.2	8.0	9.1

Source: Company, HSIE Research

### Standalone Estimate Change Summary

INR mn	FY25E			FY26E		
	New	Old	Change (%)	New	Old	Change (%)
Revenues	1,05,550	1,11,596	(5.4)	1,15,577	1,22,198	(5.4)
EBITDA	13,124	14,244	(7.9)	14,617	16,076	(9.1)
EBITDA (bps)	12.4	12.8	(33.0)	12.65	13.16	(50.8)
APAT	4,279	4,389	(2.5)	5,222	5,424	(3.7)

Source: Company, HSIE Research

## ADD

CMP (as on 10 May 2024)	INR 471
Target Price	INR 529
NIFTY	22,055

KEY CHANGES	OLD	NEW
Rating	ADD	ADD
Price Target	INR 483	INR 529
EPS Change %	FY25E	FY26E
	-2.5	-3.7

### KEY STOCK DATA

Bloomberg code	DBL IN
No. of Shares (mn)	146
MCap (INR bn) / (\$ mn)	69/824
6m avg traded value (INR mn)	510
52 Week high / low	INR 505/160

### STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	14.3	30.1	165.9
Relative (%)	12.8	18.1	148.6

### SHAREHOLDING PATTERN (%)

	Dec-23	Mar-24
Promoters	70.15	70.15
FIs & Local MFs	9.10	9.08
FPIs	2.89	2.89
Public & Others	17.86	17.89
Pledged Shares	17.53	17.53

Source: BSE

Pledged shares as % of total shares

**Parikshit D Kandpal, CFA**  
parikshitd.kandpal@hdfcsec.com  
+91-22-6171-7317


**Jay Shah**  
jay.Shah1@hdfcsec.com  
+91-22-6171-7353

**Rating Criteria**

BUY: >+15% return potential  
 ADD: +5% to +15% return potential  
 REDUCE: -10% to +5% return potential  
 SELL: > 10% Downside return potential

**Disclosure:**

Analyst	Company Covered	Qualification	Any holding in the stock
Jay Gandhi	Relaxo Footwears	MBA	NO
Tanuj Pandia	Relaxo Footwears	CA	NO
Nilesh Ghuge	Alkyl Amines	MMS	NO
Harshad Katkar	Alkyl Amines	MBA	NO
Prasad Vadnere	Alkyl Amines	MSc	NO
Akshay Mane	Alkyl Amines	PGDM	NO
Parikshit Kandpal	HG Infra, Dilip Buildcon	CFA	NO
Jay Shah	HG Infra, Dilip Buildcon	CA	NO



**Disclosure:**

We, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. SEBI conducted the inspection and based on their observations have issued advise/warning. The said observations have been complied with. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does have/does not have any material conflict of interest.

Any holding in stock – No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

**Disclaimer:**

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities

from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

Please note that HDFC Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: [complianceofficer@hdfcsec.com](mailto:complianceofficer@hdfcsec.com) Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: [customercare@hdfcsec.com](mailto:customercare@hdfcsec.com) Phone: (022) 3901 9400

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

---

**HDFC Securities**  
**Institutional Equities**

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park,  
Senapati Bapat Marg, Lower Parel, Mumbai - 400 013  
Board: +91-22-6171-7330 [www.hdfcsec.com](http://www.hdfcsec.com)